450 related articles for article (PubMed ID: 24366665)
1. Inhibition of polo-like kinase 1 promotes hyperthermia sensitivity via inactivation of heat shock transcription factor 1 in human retinoblastoma cells.
Yunoki T; Tabuchi Y; Hayashi A; Kondo T
Invest Ophthalmol Vis Sci; 2013 Dec; 54(13):8353-63. PubMed ID: 24366665
[TBL] [Abstract][Full Text] [Related]
2. BAG3 protects against hyperthermic stress by modulating NF-κB and ERK activities in human retinoblastoma cells.
Yunoki T; Tabuchi Y; Hayashi A; Kondo T
Graefes Arch Clin Exp Ophthalmol; 2015 Mar; 253(3):399-407. PubMed ID: 25471019
[TBL] [Abstract][Full Text] [Related]
3. Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines.
Schwermer M; Dreesmann S; Eggert A; Althoff K; Steenpass L; Schramm A; Schulte JH; Temming P
Clin Exp Ophthalmol; 2017 Apr; 45(3):288-296. PubMed ID: 27647547
[TBL] [Abstract][Full Text] [Related]
4. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.
Zhang Y; Du XL; Wang CJ; Lin DC; Ruan X; Feng YB; Huo YQ; Peng H; Cui JL; Zhang TT; Wang YQ; Zhang H; Zhan QM; Wang MR
Gastroenterology; 2012 Mar; 142(3):521-530.e3. PubMed ID: 22108192
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of heat shock protein response enhances PS-341-mediated glioma cell death.
Liu Y; Zheng T; Zhao S; Liu H; Han D; Zhen Y; Xu D; Wang Y; Yang H; Zhang G; Wang C; Wu J; Ye Y
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S421-9. PubMed ID: 21732139
[TBL] [Abstract][Full Text] [Related]
7. Silencing of polo-like kinase (Plk) 1 via siRNA causes inhibition of growth and induction of apoptosis in human esophageal cancer cells.
Bu Y; Yang Z; Li Q; Song F
Oncology; 2008; 74(3-4):198-206. PubMed ID: 18714168
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
Liu X; Choy E; Harmon D; Yang S; Yang C; Mankin H; Hornicek FJ; Duan Z
Anticancer Drugs; 2011 Jun; 22(5):444-53. PubMed ID: 21399492
[TBL] [Abstract][Full Text] [Related]
9. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice.
Lee C; Fotovati A; Triscott J; Chen J; Venugopal C; Singhal A; Dunham C; Kerr JM; Verreault M; Yip S; Wakimoto H; Jones C; Jayanthan A; Narendran A; Singh SK; Dunn SE
Stem Cells; 2012 Jun; 30(6):1064-75. PubMed ID: 22415968
[TBL] [Abstract][Full Text] [Related]
10. Efficient inhibition of human colorectal carcinoma growth by RNA interference targeting polo-like kinase 1 in vitro and in vivo.
Xu WJ; Zhang S; Yang Y; Zhang N; Wang W; Liu SY; Tian HW; Dai L; Xie Q; Zhao X; Wei YQ; Deng HX
Cancer Biother Radiopharm; 2011 Aug; 26(4):427-36. PubMed ID: 21797676
[TBL] [Abstract][Full Text] [Related]
11. Xanthatin Selectively Targets Retinoblastoma by Inhibiting the PLK1-Mediated Cell Cycle.
Yang J; Li Y; Zong C; Zhang Q; Ge S; Ma L; Fan J; Zhang J; Jia R
Invest Ophthalmol Vis Sci; 2021 Dec; 62(15):11. PubMed ID: 34901994
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological significance of Polo-like kinase 1 (PLK1) expression in human malignant glioma.
Cheng MW; Wang BC; Weng ZQ; Zhu XW
Acta Histochem; 2012 Sep; 114(5):503-9. PubMed ID: 22000864
[TBL] [Abstract][Full Text] [Related]
13. Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer.
Reagan-Shaw S; Ahmad N
FASEB J; 2005 Apr; 19(6):611-3. PubMed ID: 15661849
[TBL] [Abstract][Full Text] [Related]
14. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
Ding Y; Huang D; Zhang Z; Smith J; Petillo D; Looyenga BD; Feenstra K; Mackeigan JP; Furge KA; Teh BT
Cancer Res; 2011 Aug; 71(15):5225-34. PubMed ID: 21642374
[TBL] [Abstract][Full Text] [Related]
15. The antitumor effect of PLK1 and HSF1 double knockdown on human oral carcinoma cells.
Kim SA; Kwon SM; Yoon JH; Ahn SG
Int J Oncol; 2010 Apr; 36(4):867-72. PubMed ID: 20198330
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines.
Münch C; Dragoi D; Frey AV; Thurig K; Lübbert M; Wäsch R; Bogatyreva L; Hauschke D; Lassmann S; Werner M; May AM
Leuk Res; 2015 Apr; 39(4):462-70. PubMed ID: 25697066
[TBL] [Abstract][Full Text] [Related]
17. The natural compound cantharidin induces cancer cell death through inhibition of heat shock protein 70 (HSP70) and Bcl-2-associated athanogene domain 3 (BAG3) expression by blocking heat shock factor 1 (HSF1) binding to promoters.
Kim JA; Kim Y; Kwon BM; Han DC
J Biol Chem; 2013 Oct; 288(40):28713-26. PubMed ID: 23983126
[TBL] [Abstract][Full Text] [Related]
18. Fisetin, a dietary flavonoid, induces apoptosis of cancer cells by inhibiting HSF1 activity through blocking its binding to the hsp70 promoter.
Kim JA; Lee S; Kim DE; Kim M; Kwon BM; Han DC
Carcinogenesis; 2015 Jun; 36(6):696-706. PubMed ID: 25840992
[TBL] [Abstract][Full Text] [Related]
19. [Inhibition of polo like kinase gene expression induces apoptosis in gastric cancer cells].
Lan B; Liu BY; Cheng XH; Qu Y; Zhang XQ; Cai Q; Zhu ZG
Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Jan; 9(1):62-6. PubMed ID: 16437376
[TBL] [Abstract][Full Text] [Related]
20. A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies.
Ikezoe T; Yang J; Nishioka C; Takezaki Y; Tasaka T; Togitani K; Koeffler HP; Yokoyama A
Leukemia; 2009 Sep; 23(9):1564-76. PubMed ID: 19421227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]